Skip to Main Content

Try STAT+ TODAY

Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Most Read

Adam's Take Adam Feuerstein

STAT Plus: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn

Adam's Take Adam Feuerstein

STAT Plus: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy

Adam's Take Adam Feuerstein

STAT Plus: An Anavex study spin job sullies an otherwise spectacular Alzheimer’s conference

Adam's Take Adam Feuerstein

STAT Plus: Northwest Bio study of brain cancer vaccine still falls short

Adam's Take Adam Feuerstein

CytoDyn’s former CEO indicted for securities fraud. His misleading statements hurt patients even more than investors

Adam's Take Adam Feuerstein

STAT Plus: Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share

Adam's Take Adam Feuerstein

STAT Plus: Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person

Adam's Take Adam Feuerstein

STAT Plus: A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy

All Coverage

Adam's Take Adam Feuerstein

STAT Plus: With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally

Adam's Take Adam Feuerstein

STAT Plus: Not-so-happy midyear! Biotech CEOs, best and worst, and a hopeful sign of a turnaround

advertisement

Adam's Take Adam Feuerstein

STAT Plus: A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser

Adam's Take Adam Feuerstein

STAT Plus: Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen

Adam's Take Adam Feuerstein

STAT Plus: It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the open

Adam's Take Adam Feuerstein

STAT Plus: A company developing a human blood substitute attempts a comeback, but IPO plans look dicey

Adam's Take Adam Feuerstein

STAT Plus: What Regeneron’s purchase of Checkmate Pharma says about the state of biotech

Adam's Take Adam Feuerstein

STAT Plus: Cel-Sci’s CEO used private call to tip off select investors about cancer drug update

Adam's Take Adam Feuerstein

STAT Plus: Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies

Adam's Take Adam Feuerstein

STAT Plus: Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent

Adam's Take Adam Feuerstein

STAT Plus: An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more

Adam's Take Adam Feuerstein

STAT Plus: Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show

Adam's Take Adam Feuerstein

STAT Plus: An FDA rejection derails Omeros, exposing the empty promises of its CEO

Adam's Take Adam Feuerstein

STAT Plus: Northwest Bio marks ignominious anniversary of brain tumor study delay with silence

Adam's Take Adam Feuerstein

STAT Plus: In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s

Adam's Take Adam Feuerstein

STAT Plus: Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

Adam's Take Adam Feuerstein

STAT Plus: The failure of a cancer drug study leaves Cel-Sci on the brink of collapse

Adam's Take Adam Feuerstein

STAT Plus: FDA issues major rebuke to CytoDyn over claims on Covid-19 drug

Adam's Take Adam Feuerstein

STAT Plus: Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug

Adam's Take Adam Feuerstein

STAT Plus: Fibrogen’s data manipulation scandal came with questions. There need to be answers

Adam's Take Adam Feuerstein

STAT Plus: The long wait for Cel-Sci to finally admit its cancer drug doesn’t work

Adam's Take Adam Feuerstein

STAT Plus: A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists

Adam's Take Adam Feuerstein

STAT Plus: CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment

Adam's Take Adam Feuerstein

STAT Plus: Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

Adam's Take Adam Feuerstein

STAT Plus: Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list